The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after ...

The BC Cancer Foundation has launched a $6.8 million fundraising campaign to expand provincial immunotherapy research program ...

Citius Oncology, Inc. ("Citius Oncology" or the "Company") , a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported ...

The influenza A virus genome consists of eight segments of single-stranded, negative-sense viral RNA, which encode multiple ...

Interrupting signals exchanged between tumors and the nervous system could become a critical pillar of cancer care ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...